Intellia Therapeutics, INC 8-K filings

Intellia Therapeutics reported positive Phase 3 HAELO trial data for lonvo-z in HAE, anticipates FDA BLA submission in H2 2026, and maintains a strong cash position extending into 2028.

Intellia Therapeutics announced additional positive Phase 3 results for its hereditary angioedema treatment, lonvoguran ziclumeran (lonvo-z), showing significant reductions in monthly attacks and improved quality of life.

Intellia Therapeutics held its annual meeting on June 9, 2026, where shareholders elected directors, ratified auditor appointment, and approved executive compensation.

Intellia Therapeutics reported Q1 2026 results, highlighting positive Phase 3 data for lonvo-z in HAE, initiation of a rolling BLA submission, and resumption of ATTR trials, with cash runway extended into 2028.

Intellia Therapeutics has successfully completed a public offering of common stock, raising approximately $194.6 million in net proceeds to fund clinical development and operations.

Intellia Therapeutics announced positive topline results from its Phase 3 HAELO trial for lonvo-z in hereditary angioedema, meeting primary and secondary endpoints and initiating a rolling BLA submission.

Intellia Therapeutics, Inc. has amended its bylaws to allow shareholders to cure notice deficiencies and designate federal courts as the exclusive forum for securities-related lawsuits.

Intellia Therapeutics increased its at-the-market offering program to over $1 billion and announced the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial for ATTR-CM.

Intellia Therapeutics announced its fourth quarter and full-year 2025 financial results and provided key business updates on its CRISPR gene editing programs, lonvo-z and nex-z.

Intellia Therapeutics announced the FDA has removed the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTRv-PN, allowing patient enrollment to resume.

Intellia Therapeutics reports a clinical hold on its Phase 3 nexiguran ziclumeran trials following a patient death due to septic shock, while its lonvoguran ziclumeran program advances towards a 2027 launch.

Intellia Therapeutics announced positive long-term clinical data for its gene-editing therapies lonvo-z for HAE and nex-z for ATTR amyloidosis, though its nex-z Phase 3 trials are under an FDA clinical hold.

Intellia Therapeutics announced Q3 2025 financial results and a clinical hold on its nex-z trials following a patient death, while its lonvo-z trial progresses.

The FDA has placed a clinical hold on Intellia Therapeutics' MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nexiguran ziclumeran following a serious adverse event.

Intellia Therapeutics has temporarily halted its Phase 3 clinical trials for nexiguran ziclumeran (nex-z) following a serious liver-related adverse event in a patient, impacting its ATTR amyloidosis programs.

Intellia Therapeutics announced positive longer-term Phase 1 data for its gene editing therapy, nexiguran ziclumeran (nex-z), showing deep and durable TTR reductions and clinical improvements in ATTRv-PN patients.

Intellia Therapeutics reports strong Q2 2025 financial results and significant progress in its late-stage clinical programs, including expanded enrollment for its ATTR-CM trial and accelerated completion of its HAE study, alongside the announcement of its CMO's retirement.

Intellia Therapeutics announced highly positive three-year follow-up data from its Phase 1 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE), showing a 98% reduction in attack rates and favorable safety, while also confirming early completion of Phase 3 trial screening.

Intellia Therapeutics, Inc. announced that its stockholders approved the 2025 Equity Incentive Plan, elected three Class III directors, ratified Deloitte & Touche LLP as auditors, and voted on executive compensation and its frequency at the 2025 Annual Meeting.

Intellia Therapeutics provided a positive business update on its ongoing Phase 3 clinical trials for hereditary angioedema and ATTR amyloidosis, confirming enrollment progress and maintaining timelines for potential U.S. commercial launches.

Intellia Therapeutics reports positive two-year follow-up data from its Phase 1 study of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy, showing sustained TTR reductions and clinical improvements.

Intellia Therapeutics reports its Q1 2025 financial results, highlighting progress in clinical trials for hereditary angioedema (HAE) and ATTR amyloidosis.

Intellia Therapeutics updated its by-laws to include a majority vote standard for uncontested director elections and implement proxy solicitation procedures, effective April 3, 2025.

Intellia Therapeutics reports advancements in its Phase 3 clinical trials for NTLA-2002 and nexiguran ziclumeran, along with a solid cash position to fund operations into the first half of 2027.

Intellia Therapeutics secures a new lease for office and laboratory space in Cambridge, Massachusetts, while amending its existing lease in Waltham.

Intellia Therapeutics is prioritizing its late-stage clinical programs, NTLA-2002 and nexiguran ziclumeran (nex-z), leading to a strategic restructuring and a 27% workforce reduction.

Intellia Therapeutics reports positive Phase 1 clinical trial results for nexiguran ziclumeran (nex-z), a CRISPR-based gene editing therapy, showing potential for disease stabilization and improvement in patients with transthyretin (ATTR) amyloidosis.

Intellia Therapeutics announced positive clinical trial advancements and financial results for the third quarter of 2024, highlighting progress in their CRISPR-based gene editing therapies.

Intellia Therapeutics reports positive Phase 2 results for NTLA-2002, a CRISPR gene editing therapy, showing significant reductions in hereditary angioedema attacks.

Intellia Therapeutics reports positive results from its Phase 2 study of NTLA-2002 for hereditary angioedema, selects a dose for Phase 3, and provides updates on other clinical programs.